TEXT +-

Diagnosing MacTel

For Healthcare Providers

mactel-common-symptoms

Macular Telangiectasia type 2 is a rare disease of the retina that leads to a gradual loss of central vision. MacTel is estimated to affect about 0.1% of the population, and its onset is age-related. Affected individuals are typically diagnosed in their 50s and 60s. MacTel is sometimes mistaken for age-related macular degeneration, due to similar patterns of neovascularization in both diseases.

MacTel is a bilateral disease. Fellow eyes are usually similarly affected by the disease, showing the same pathological features. However, the disease may progress at a different rate in each eye.

The retinal alterations caused by MacTel usually begin in a temporal paracentral area. Retinal changes are most pronounced on the temporal side of the retina. Microperimetry and OCT studies to assess function and structure, respectively, suggest that the area temporal to the fovea can be considered the epicenter of disease.

As MacTel progresses, it may encompass an oval region with a radius of about 6⁰ horizontally and 5⁰ vertically, centered on the foveola. Alternatively, MacTel may affect a circular region of the retina, centered on the foveola. MacTel may also be restricted to the temporal macula, leaving the nasal side mostly unaffected.

A report published by members of the MacTel Project describes the macular changes that may be observed in Macular Telangiectasia type 2 patients.

Early signs and symptoms of MacTel:

    • Blunting or lack of the foveolar reflex. This observation is restricted to early-stage disease.
    • Crystalline deposits, located in the inner retina at the level of the inner limiting membrane. They may appear as hyperreflective dots at the anterior surface of the nerve fiber layer in OCT scans. The deposits are present at all stages of disease. In participants of the MacTel Natural History Study, 46% of patients had crystalline deposits. For those with deposits, 60% showed deposits bilaterally.
    • Reduced retinal transparency in the parafoveolar area may be one of the first visible changes in the retina. This symptom is also referred to as retinal graying.

mactel-earlysigns

Common symptoms of MacTel:

    • Mildly ectatic capillaries affect primarily the deeper capillary network, though telangiectatic vessels have been observed in inner and outer retinal circulation.
    • Blunted, slightly dilated venules are often associated with ectatic capillaries and, in later disease stages, with retinal pigment plaques. These vessels don’t appear to narrow as they approach the foveola, rather, they suddenly seem to dive at right angles into the deeper retinal layers.
    • Foveal atrophy. This may appear as small foveal non-prominent cysts, or a pseudo-lamellar macular hole, or as slightly altered foveal reflectivity. Atrophy can be missed on fundus images. Atrophy of the outer retinal photoreceptor layer is the endpoint of MacTel, and results in localized loss of visual function.
    • Abnormal distribution of macular pigment. Macular pigment deposition is normally concentrated in the fovea. In MacTel eyes, there is a loss of macular pigment from the central retina. Instead, MacTel eyes show a ring of pigments about 12 degrees in diameter, much larger than the normal 1-2 degrees in diameter. This can be visualized with autofluorescence imaging. Dietary supplementation with lutein and zeaxanthin enhanced the existing ring of macular pigments, but it did not restore normal macular pigment distribution.
    • Retinal pigment plaques (pigment-hyperplasia) seem to originate from small foci of RPE hyperplasia that migrate into the neurosensory retina. Photoreceptor atrophy precedes, and may cause, the presence of retinal pigment plaques. Retinal pigment plaques may be surrounded by RPE atrophy.

 

Rarely observed features of MacTel:

  • A small round yellow spot may be found centered on the fovea, roughly ½-disc diameter size.
  • Small retinal hemorrhages in the absence of a neovascular complex. These are transient, usually resolving in a few weeks.
  • True lamellar, or full thickness macular holes, may occur. This is a complication of the disease, possibly resulting from the progressive degeneration and atrophy of the retina. Cellular death may destabilize the fovea, leading to a macular hole which may be more difficult to surgically treat than other types of macular holes.
  • Neovascular complexes may develop at any time point, and complicate the natural course of the disease. These are most commonly located temporal to the foveola. They seem to originate from the retinal vasculature, not the choroid as is seen in age-related macular degeneration. In MacTel, these neovascular complexes may, however, still gain access to the subretinal space and develop chorio-retinal shunts.

Diagnosing MacTel with Retinal Imaging:

Fluorescein angiography is commonly used to detect vascular alterations that occur due to MacTel. Fluorescein angiography typically shows telangiectatic capillaries temporal to the foveola in early-stage MacTel. In late-stage disease, fluorescein angiography shows a diffuse hyperfluoresence. It should be noted that MacTel causes retinal changes that cannot be seen by fluorescein angiography. This tool will not be effective, alone, to detect early cases of MacTel.

Optical coherence tomography (OCT) is a non-invasive imaging technique that uses long-wavelength light to generates high-resolution images of the retina in cross-section. OCT can be used to detect changes related to MacTel, at very early stages. OCT shows asymmetry in the foveal dip very early. It also shows hyporeflective cavities of the inner and outer neurosensory MacTel retina, and increased reflectivity of inner neurosensory layers. Importantly, OCT is used to measure the IS/OS break, which is the disruption of the border between inner and outer photoreceptor segments, and has been one of the inclusion criteria for participation in clinical studies.

Confocal Reflectance Imaging with a blue laser at 488 nm shows an increased reflectance in the parafoveolar region of MacTel eyes, surrounded by decreased reflectivity. This has also been referred to as “Blue light reflectance imaging.” The images can be captured with a fundus camera and confocal scanning laser ophthalmoscope. The area of increased reflectance is coincident with the loss of macular pigment. Imaging macular pigment loss is a more reliable marker of early disease.

Macular Pigment Density can be imaged in MacTel by a variety of techniques: two-wavelength fundus autofluorescence, two-wavelength reflectance maps, and spectral fundus reflectometry.

Confocal Adaptive Optics Scanning Laser Ophthalmoscopy is a non-invasive imaging technique that can be used to see individual photoreceptors in the back of the eye, along with other features, like cysts, blood vessels, and the RPE cell layer. Using adaptive optics, it is possible to begin to understand how MacTel affects photoreceptor health and function. Adaptive optics is time-consuming and requires very specialized instrumentation.  Adaptive optics imaging is not widely available, and is not appropriate for diagnostic purposes, but it is being used in the ongoing clinical trials.

United Kingdom

Moorfields Eye Hospital
London, United Kingdom
Cathy Egan, MD
011 44 20 7566 2262
catherine.egan@moorfields.nhs.uk

×
United States

California

Scripps Research Institute
La Jolla, CA USA
Martin Friedlander, MD, PhD
858-784-9138
friedlan@scripps.edu

Jules Stein Eye Institute, UCLA
Los Angeles, CA USA
Jean-Pierre Hubschman, MD
310-206-5004
hubschman@jsei.ucla.edu

Florida

Bascom Palmer Eye Institute, University of Miami
Miami, FL USA
Philip Rosenfeld, MD
305-326-6538
prosenfeld@med.miami.edu

Massachusetts

Massachusetts Eye and Ear Infirmary
Boston, MA USA
Joan Miller, MD
617-578-3257
joan.miller@meei.harvard.edu

Michigan

University of Michigan, Kellogg Eye Center
Ann Arbor, MI USA
Grant Comer, MD
734-763-5906
gcomer@umich.edu

New York

Manhattan Eye, Ear & Throat Hospital
New York, NY USA
Michael Cooney, MD
212 861-9797
m.cooney@vrmny.com

The New York Eye and Ear Infirmary
New York, NY USA
Richard Rosen, MD
212-979-4284
rrosen@nyee.edu

Ohio

Retina Associates of Cleveland, Inc.
Cleveland, OH USA
Lawrence Singerman, MD
216-831-5700
lsingerman@retina-assoc.com

Pennsylvania

Scheie Eye Institute
Philadelphia, PA USA
Alexander Brucker, MD
215-662-8675
ajbrucke@mail.med.upenn.edu

Utah

University of Utah Medical Center
Salt Lake City, Utah
Paul Bernstein, MD, PhD.
801-581-6078
paul.bernstein@hsc.utah.edu

Virginia

The Retina Group of Washington
Fairfax, VA USA
Robert Murphy, MD
703-698-9335
rpmurphy@comcast.net

Wisconsin

University of Wisconsin
Madison, WI USA
Barbara Blodi, MD
608-263-6646
bablodi@wisc.edu

×
France

Hopital Lariboisiere
Paris, France
Alain Gaudric, MD
011 33 1 4995 2475
alain.gaudric@lrb.aphp.fr

×
Germany

Universitats-Augenklinik Bonn
Bonn, Germany
Frank Holz, MD
011 49 228 287 5647
Frank.Holz@ukb.uni-bonn.de

St. Franziskus Hospital
Muenster, Germany
Prof. Daniel Pauleikhoff
dapauleikhoff@muenster.de
Bjorn Padge, MD
011 49-251-93308-0
bjoern@padge.de

×
Israel

The Goldschleger Eye Institute
Tel Hashomer, Israel
Joseph Moisseiev, MD
011 972 3 5343462
Joseph.moisseiev@sheba.health.gov.il

×
Switzerland

Klinik und Poliklinik fur Augenheilkunde
Inselspita
University of Bern
Bern, Switzerland
Sebastian Wolf, MD, PhD
41 31 6328503
sebastian.wolf@insel.ch

×
Australia

Center for Eye Research Australia
Melbourne, Australia
Robyn Guymer, MD
011 61 3 9929 8393
rhg@unimelb.edu.au

Lions Eye Institute
Nedlands, Australia
Ian Constable, MD
011 61 8 9381 0882
ijc@cyllene.uwa.edu.au

Save Sight Institute
Sydney NSW Australia
Mark Gillies, MD, PhD
011 61 412 060 313
mark.gillies@sydney.edu.au

×